Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

ClinicalTrials.gov ID: NCT06508320

Public ClinicalTrials.gov record NCT06508320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity in Relation to the Product Attributes of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Adults ≥50 to <65 Years of Age

Study identification

NCT ID
NCT06508320
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ModernaTX, Inc.
Industry
Enrollment
932 participants

Conditions and interventions

Interventions

  • mRNA-1083 Biological

Biological

Eligibility (public fields only)

Age range
50 Years to 64 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 14, 2024
Primary completion
Sep 24, 2025
Completion
Sep 24, 2025
Last update posted
Oct 13, 2025

2024 – 2025

United States locations

U.S. sites
12
U.S. states
7
U.S. cities
12
Facility City State ZIP Site status
Indago Research & Health Center, Inc. Hialeah Florida 33012
Cenexel RCA Hollywood Florida 33024
Suncoast Research Group, LLC DBA Flourish Research Miami Florida 33135
Cenexel IRA Decatur Georgia 30030
DM Clinical Research - River Forest River Forest Illinois 60305
JCCT Lenexa Kansas 66219
Hassman Research Institute - Berlin - CenExel - PPDS Marlton New Jersey 80530
DM Clinical Research - Philadelphia Philadelphia Pennsylvania 19107
DM Clinical Research - Cyfair Clinical Research Center - PPDS Houston Texas 77065-5685
Clinical Trials of Texas, LLC DBA Flourish Research San Antonio Texas 78229
DM Clinical Research - Sugarland Sugar Land Texas 77478
DM Clinical Research - Tomball MDC Tomball Texas 77375

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06508320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06508320 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →